Article

Isolation and characterization of neutralizing monoclonal antibodies from a large panel of murine antibodies against RBD of the SARS-CoV-2 Spike protein

2023-07-14

Abstract excerpt

<title>Abstract</title> <p>Background Coronavirus disease 2019 (COVID-19) emerged in late December 2019 and was declared pandemic in March 2020 by the World Health Organization, causing clinically acute respiratory manifestations and corresponding symptoms, pathological inflammation and multi-organ dysfunctions. The total commitment of the scientific community to develop therapeutics to deal with this global emer...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: c340868e-d171-5e1a-bc46-5de0d0af1b1b
DOI: 10.21203/rs.3.rs-3142062/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Isolation and characterization of neutralizing monoclonal antibodies from a large panel of murine antibodies against RBD of the SARS-CoV-2 Spike proteinDOI 10.21203/rs.3.rs-3142062/v1Read

Establishment of murine hybridoma cells producing antibodies against spike protein of SARS-CoV-2Semantic proximity Read

Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodiesSemantic proximity Read

An <i>in vitro</i> experimental pipeline to characterize the binding specificity of SARS-CoV-2 neutralizing antibodiesSemantic proximity Read

A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike proteinSemantic proximity Read

The receptor-binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patientsSemantic proximity Read

A proof of concept for neutralizing antibody-guided vaccine design against SARS-CoV-2Semantic proximity Read

Mapping cross-variant neutralizing sites on the SARS-CoV-2 spike proteinSemantic proximity Read

Targeting SARS-CoV2 Spike Protein Receptor Binding Domain by Therapeutic AntibodiesSemantic proximity Read

Broad ultra-potent neutralization of SARS-CoV-2 variants by monoclonal antibodies specific to the tip of RBDSemantic proximity Read

Development of a neutralization monoclonal antibody with a broad neutralizing effect against SARS-CoV-2 variantsSemantic proximity Read

The RBD Of The Spike Protein Of SARS-Group Coronaviruses Is A Highly Specific Target Of SARS-CoV-2 Antibodies But Not Other Pathogenic Human and Animal Coronavirus AntibodiesSemantic proximity Read

A Novel Neutralizing Antibody Targeting Receptor Binding Domain of SARS-CoV-2Semantic proximity Read